N/A
- Pharmaceuticals
- HIV-Associated Nephropathy Market
HIV-Associated Nephropathy Market
HIV-Associated Nephropathy Market: Global Industry Trend Analysis 2013 to 2017 and Forecast 2018 - 2028
Market Overview:
Human immunodeficiency virus (HIV) affects kidney function in patients. HIV-positive patients are at increased risk for a variety of renal disorders. HIV-associated nephropathy (HIVAN) is also one of the kidney disorder which affects HIV-positive patients.
HIV-associated nephropathy (HIVAN) was first described in 1984 as the complication of acquired immune deficiency syndrome. HIV-associated nephropathy (HIVAN) starts with a large amount of protein in the urine and progresses rapidly to total kidney failure.
Antiretroviral therapy preserved kidney function in patients with HIV. Treatment with Antiretroviral drugs reduced the risk of the HIV-associated nephropathy. HIV Medicine Association and Infectious Diseases Society of America recommended the use of antiretroviral drugs (ART) for patients with HIV-associated nephropathy. In the various clinical studies, it’s suggested that corticosteroids and ACE inhibitors are also beneficial for the treatment of HIV-associated nephropathy.
The global market for HIV-associated nephropathy is expected to witness significant and continuous growth over the forecast period due to the rising number of HIV cases. In 2017, estimated 36.9 Mn people are suffered from HIV globally. Government and private organization take initiative to reduce the number of cases of HIV and support HIV treatment.
These are the major factor expected to propel the growth of the HIV-associated nephropathy market. The program such as UNAIDS’ 90-90-90 is initiated for the prevention and treatment of HIV and associated disorders. Increasing HIV treatment access expected to favors the growth of the HIV-associated nephropathy market.
According to Avert Organization, in 2017, around 59% of all people living with HIV were accessing treatment as compared to past years. Moreover, in 2017, 21.7 Mn people living with HIV were receiving ART therapy which increased by 2.3 Mn from 2016.
However, side effects associated with long-term use of ART expected to restrain the growth of the HIV-associated nephropathy market. Long-term use of ART therapy has been linked to various other diseases such as diabetic nephropathy and focal segmental glomerulosclerosis.
The report covers exhaustive analysis:
- HIV-Associated Nephropathy Market Segments
- HIV-Associated Nephropathy Market Dynamics
- Historical Actual Market Size, 2013 - 2017
- HIV-Associated Nephropathy Market Size & Forecast 2018 to 2026
- HIV-Associated Nephropathy Market Current Trends/Issues/Challenges
- Competition & Companies involved
- HIV-Associated Nephropathy Market Drivers and Restraints
Report Highlights:
- Shifting industry dynamics
- In-depth market segmentation
- Historical, current and projected industry size recent industry trends
- Key competition landscape
- Strategies of key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
